Study for personalized medicine based on pharmacokinetics and pharmacodynamics concerned with therapeutic drug of nontuberculous mycobacterium.
- Conditions
- patients administered with therapeutic drug of nontuberculous mycobacterium
- Registration Number
- JPRN-UMIN000020406
- Lead Sponsor
- Center for Infectious Disease and Infection Control
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Not provided
(1) It is the patient with a history of the drug allergy in EB, CAM, RFP (2) HIV infection therapeutic drug (indinavir sulfate ethanol addition, saquinavir mesilate, nelfinavir mesilate, L biTaegu rabbi a type of radical preparation including), voriconazole, praziquantel, Tadalafil, terra pre-building, Japanese hawfinch pre-building sodium, pimozide, ergotamine component preparation, the patients receiving etc., (3) In the patients with impaired liver or kidney, it is the patient receiving the colchicine (4) The patients with biliary tract obstruction or the serious liver damage (5) Optic neuritis, patients with diabetes, patients with alcoholism (6) For an infection related to this medicine insusceptibility pathogen or resistant strain, it is the patient who is judged clinically when it is hard to expect an effect with this medicine (7) Pregnant woman, the patients nursing, the patients who may be pregnant (8) In addition, the patients who judged that it was inadequate as an object of this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method